Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC 90-1170 (liraglutide) mechanism of action in obese T2D
NCT01508949Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2001
- Primary completion
- Mar 2002
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and obesity comparing NNC 90-1170 with Placebo (2 arms). Primary endpoint: Change in weight at 8 weeks. Started Jun 2001; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT01508949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01508949.